Colorectal cancer has the 2nd highest incidence rate in the world and has become the 3rd most deadly cancer in developing countries. Liver is the most likely site for distant metastases of colorectal cancer, and liver metastases account for 60%-7l% of deaths of colorectal cancer patients. The natural survival time of untreated colorectal cancer liver metastases (CRCLM) patients is 16-18 months, and the 4-year survival rate is close to 0, while the 5-year survival rate of patients who undergo surgical resection can reach more than 50%. In recent years, radiofrequency ablation (RFA) has been used in patients with CRCLM that can be surgically resected and in combination with unresectable CRCLM. The main reasons for the survival benefit of RFA in combination with chemotherapy can be attributed to (1) the complete killing of residual chemotherapy lesions, (2) the possibility of prolonging the chemotherapy interval and effectively restoring the patient’s physical condition for subsequent combination therapy, and (3) the fact that some patients with hepatic metastases treated with RFA exhibit a significant increase in the number of patients with liver metastases. RFA treatment shows complete remission of imaging,, and also facilitates the adjustment of patients’ psychological status. The technical aspect of RFA with combined chemotherapy requires attention to the scope of ablation, which theoretically includes all the original sites of lesions, in order to achieve a high local control rate. The effective sequential use of RFA for liver metastases in combination with chemotherapy, targeted drugs or surgery can significantly prolong the survival time of patients compared to conventional treatment. Individualized comprehensive treatment refers to an individualized comprehensive treatment plan based on patient’s specific conditions at different stages of disease development, different aspects and conditions, combined with evidence-based medical evidence, with one treatment modality as the main modality and other treatment modalities as supplementary modalities, in order to achieve the maximum improvement of patient’s survival quality and prolongation of survival. The incidence of colorectal cancer in China has been increasing significantly in recent years, and the rate of incidence growth in Shanghai, Beijing and other major cities has far exceeded that of western countries. The median age of onset of colorectal cancer in China is about 10 years earlier than that in Europe and the United States, and young patients are more common than those in Europe and the United States. The insidious onset of colorectal cancer, the high number of patients in the middle and late stages, and the unsatisfactory treatment effect are the current challenges faced by clinicians. Therefore, standardized colorectal cancer treatment is a necessary guarantee to improve the efficacy, which requires the close cooperation of multidisciplinary departments such as surgical oncology, medical oncology, radiotherapy, diagnostic imaging and pathology. Only by carefully evaluating the patient’s disease status and fully considering the patient’s family, economic situation and expectations of treatment before treatment can a reasonable individualized and comprehensive treatment plan be formulated. In order to improve the efficacy of colorectal cancer liver metastasis patients, the Cancer Hospital of Chinese Academy of Medical Sciences has established the “MDT Expert Committee for Colorectal Cancer Liver Metastasis” to conduct comprehensive consultation with all experts before treatment for each patient, and reasonably arrange the treatment measures such as preoperative systemic chemotherapy, surgical resection, radiofrequency ablation therapy, postoperative synchronous radiotherapy and postoperative adjuvant chemotherapy. The treatment measures such as adjuvant chemotherapy are expected to make the patients’ primary rectal lesions and liver metastases get radical treatment, while considering whether the sequence of comprehensive treatment aggravates patients’ combined diseases and increases post-treatment complications, reflecting the advantages of individualized comprehensive treatment concept. Due to the combined application of neoadjuvant therapy, laparoscopic adjuvant, intraoperative radiofrequency ablation, and surgical resection, colorectal cancer liver metastasis has gradually become a curable disease with a better prognosis.